Ephenidine

Ephenidine
Legal status
Legal status	AU: Unscheduled; CA: Schedule I; DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act; Illegal in Sweden;
Identifiers
	IUPAC name N-Ethyl-1,2-diphenylethylamine;
CAS Number	60951-19-1; HCl: 6272-97-5;
PubChem CID	110821; HCl: 110820;
ChemSpider	99470; HCl: 99469;
UNII	NG69VG2948;
CompTox Dashboard (EPA)	DTXSID601032416 ;
Chemical and physical data
Formula	C16H19N
Molar mass	225.335 g·mol−1
3D model (JSmol)	Interactive image; HCl: Interactive image;
	SMILES CCNC(CC1=CC=CC=C1)C2=CC=CC=C2; ; HCl: CCNC(CC1=CC=CC=C1)C2=CC=CC=C2.Cl;
	InChI InChI=1S/C16H19N/c1-2-17-16(15-11-7-4-8-12-15)13-14-9-5-3-6-10-14/h3-12,16-17H,2,13H2,1H3; Key:IGFZMQXEKIZPDR-UHFFFAOYSA-N; ; HCl: InChI=1S/C16H19N.ClH/c1-2-17-16(15-11-7-4-8-12-15)13-14-9-5-3-6-10-14;/h3-12,16-17H,2,13H2,1H3;1H; Key:WOSDTAOMYCNNJE-UHFFFAOYSA-N;

Ephenidine (also known as NEDPA and EPE) is a dissociative anesthetic that has been sold online as a designer drug.^[1]^[2] It is illegal in some countries as a structural isomer of the banned opioid drug lefetamine, but has been sold in countries where it is not yet banned.^[3]^[4]

^ Morris H, Wallach J (July–August 2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–32. doi:10.1002/dta.1620. PMID 24678061.
^ Meyer MR, Orschiedt T, Maurer HH (February 2013). "Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein". Toxicology Letters. 217 (2): 137–42. doi:10.1016/j.toxlet.2012.12.012. PMID 23273999.
^ Wink CS, Meyer GM, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (October 2014). "Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS". Drug Testing and Analysis. 6 (10): 1038–48. doi:10.1002/dta.1621. PMID 24591097.
^ Wink CS, Meyer GM, Meyer MR, Maurer HH (November 2015). "Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps". Toxicology Letters. 238 (3): 39–44. doi:10.1016/j.toxlet.2015.08.012. PMID 26276083.

[1] Morris H, Wallach J (July–August 2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–32. doi:10.1002/dta.1620. PMID 24678061.

[2] Meyer MR, Orschiedt T, Maurer HH (February 2013). "Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein". Toxicology Letters. 217 (2): 137–42. doi:10.1016/j.toxlet.2012.12.012. PMID 23273999.

[Wink_2014-3] Wink CS, Meyer GM, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (October 2014). "Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS". Drug Testing and Analysis. 6 (10): 1038–48. doi:10.1002/dta.1621. PMID 24591097.

[4] Wink CS, Meyer GM, Meyer MR, Maurer HH (November 2015). "Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps". Toxicology Letters. 238 (3): 39–44. doi:10.1016/j.toxlet.2015.08.012. PMID 26276083.

[1]

[2]

[3]

[4]